BCR and chronic myelogenous leukemia, BCR-ABL1 positive: For the tet-off BCR-ABLp210 transgenic model and when BCR-ABLp210 expression was shut off, CML LSCs persisted in vivo and upon re-expression of BCR-ABLp210 they were able to initiate leukemia in secondary recipients [31].